Stereotactic Ablative Radiotherapy for Primary Kidney Cancer: UK Cohort and Protocol.

What is it about?

This study presents the first single-institution UK cohort of 19 patients with primary renal cell carcinoma (RCC) receiving protocol-based stereotactic ablative radiotherapy (SABR) with prospective follow-up. The treatment was well-tolerated, with no significant acute side effects, and the local control rate at 6 and 12 months was 94.4%. The mean drop from baseline in estimated glomerular filtration rate (eGFR) at 6 months was 5.4 ml/min, and at 12 months, it was 8.7 ml/min. The overall survival rate was 94.7% at 6 months and 78.3% at 12 months. The study also describes the treatment and planning technique used for both CyberKnife and standard Linear Accelerator platforms.

Featured Image

Why is it important?

This research is important because it presents the first single-institution UK cohort of patients with primary renal cell carcinoma (RCC) receiving protocol-based stereotactic ablative radiotherapy (SABR) with prospective follow-up. The study demonstrates that SABR is a safe and feasible treatment option for medically unfit patients with primary RCC, and it can be delivered in most UK cancer centres using standard Linear Accelerator as well as CyberKnife platforms. The research contributes to the increasing interest in the delivery of SABR to primary RCC in the United Kingdom, and it provides valuable insight into the treatment and planning technique used for both CyberKnife and standard Linear Accelerator platforms. Key Takeaways: 1. SABR is a safe and feasible treatment option for medically unfit patients with primary RCC. 2. SABR can be delivered in most UK cancer centres using standard Linear Accelerator as well as CyberKnife platforms. 3. The study presents the first single-institution UK cohort of patients with primary RCC receiving protocol-based SABR with prospective follow-up. 4. Early toxicity and local control are promising, but further follow-up is needed. 5. SABR offers the option of non-invasive ablation and conserves renal function.